Skip to main content
SpringerLink
Log in

Two-dimensional gel analysis of apoptosis-specific p53 isoforms induced by 2-methoxyestradiol in human lung cancer cells

  • Published:
Apoptosis Aims and scope Submit manuscript

Abstract

The natural metabolic byproduct of estradiol, 2-methoxyestradiol (2-MeOE2), induces apoptosis in human lung cancer cells by a p53-dependent mechanism. The expression of wild-type p53 isoforms was investigated in H1299 non-small cell lung carcinoma cells induced into apoptosis by 2-MeOE2. H1299 cells lack endogenous p53 and undergo predominantly a G1 arrest when infected with a recombinant wild-type p53 adenovirus. However, when H1299 cells transfected with p53 were treated with 2-MeOE2, they underwent rapid and extensive apoptosis. H1299 cells expressing mutant his273 p53 were unaffected by 2-MeOE2, indicating a dependence of 2-MeOE2-mediated apoptosis on the presence of a functional p53. Analysis of wild-type p53 phosphoisoforms in H1299 cells by two-dimensional gel electrophoresis revealed that 2-MeOE2 induced a unique group of acidic p53 isoforms. Although most of the wild-type p53 in untreated H1299 cells migrated as at least five diffuse species with isoelectric points from pH 5.5–6.3, as many as nine additional forms migrating toward the acidic region with pI values from 4.4–5.3 were detected in 2-MeOE2-treated apoptotic cells. Two other agents known to induce apoptosis, vinblastine and actinomycin D, induced a similar pattern of acidic p53 species as that observed for 2-MeOE2. The results indicated that the induction of apoptosis in H1299 cells by 2-MeOE2 is dependent on the upregulation of specific p53 isoforms. Identification of the specific p53 phosphoisoforms induced by MeOE2 will be an important step in understanding the regulation and function of p53 in apoptosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Tarunina M, Jenkins JR. Human p53 binds DNA as a protein homodimer but monomeric variants retain full transcriptional transactivation. Oncogene 1993; 8: 3165–3173.

    Google Scholar 

  2. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992; 70: 523–526.

    Google Scholar 

  3. Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989; 57: 1083– 1093.

    Google Scholar 

  4. Johnson P, Gray D, Mowat M, Benchimol S. Expression of wild-type p53 is not compatible with continued growth of p53-negative tumor cells. Mol Cell Biol 1991; 11: 1–11.

    Google Scholar 

  5. Yonish-Rouach E, Grunwald D, Wilder S, et al. p53-mediated cell death: relationship to cell cycle control. Mol Cell Biol 1993; 13: 1415–1423.

    Google Scholar 

  6. Debbas M, White E. Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Develop 1993; 7: 546– 554.

    Google Scholar 

  7. Merritt AJ, Potten CS, Kemp CJ, et al. The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. Cancer Res 1994; 54: 614–617.

    Google Scholar 

  8. Bendori R, Resnitzky D, Kimchi A. Changes in p53 mRNA expression during terminal differentiation of murine erythroleukemia cells. Virology 1987; 161: 607–611.

    Google Scholar 

  9. Oren M, Reich NC, Levine AJ. Regulation of the cellular p53 tumor antigen in teratocarcinoma cells and their differentiated progeny. Mol Cell Biol 1983; 2: 443–449.

    Google Scholar 

  10. Aloni-Grinstein R, Zan-Bar I, Alboum I, Goldfinger N, Rotter V. Wild type p53 functions as a control protein in the differentiation pathway of the B-cell lineage. Oncogene 1993; 8: 3297–3305.

    Google Scholar 

  11. Lane DP. p53, guardian of the genome. Nature 1992; 358: 15–16.

    Google Scholar 

  12. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51: 6304–6311.

    Google Scholar 

  13. Zhan Q, Carrier F, Fornace AJ. Induction of cellular p53 activity by DNA-damaging agents and growth arrest. Mol Cell Biol 1993; 13: 4242–4250.

    Google Scholar 

  14. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD. Altered cell cyce arrest and gene amplification potential accompany loss of wild-type p53. Cell 1992; 70: 923–925.

    Google Scholar 

  15. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 1992; 70: 937–948.

    Google Scholar 

  16. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855–4878.

    Google Scholar 

  17. Chen P-L, Chen YM, Bookstein R, Lee W-H. Genetic mechanisms of tumor suppression by the human p53 gene. Science 1990; 250: 1576–1580.

    Google Scholar 

  18. Fukasawa K, Sakoulas G, Pollack RE, Chen S. Excess wild-type p53 blocks initiation and maintenance of simian virus 40 transformation. Mol Cell Biol 1991; 11: 3472–3483.

    Google Scholar 

  19. Eliyahu D, Raz A, Gruss P, Givol D, Oren M. Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature 1984; 312: 646–649.

    Google Scholar 

  20. Hinds PW, Finlay CA, Quartin RS, et al. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the “hot-spot” mutant phenotypes. Cell Growth Diff 1990; 1: 571–580.

    Google Scholar 

  21. Shaulsky G, Goldfinger N, Rotter V. Alterations in tumor development in vivo mediated by expression of wild-type or mutant p53 proteins. Cancer Res 1991; 51: 5232–5237.

    Google Scholar 

  22. Dittmer D, Pati S, Zambetti G, et al. Gain of function mutations in p53. Nature Genet 1993; 4: 42–45.

    Google Scholar 

  23. Selkirk JK, He CY, Patterson RM, Merrick BA. Tumor suppressor p53 gene forms multiple isoforms-evidence for single locus origin and cytoplasmic complex formation with heat shock proteins. Electrophoresis 1996; 17: 1764–1771.

    Google Scholar 

  24. Milne DM, Palmer RH, Campbell DG, Meek DW. Phosphorylation of the p53 tumour-suppressor protein at three Nterminal sites by a novel casein kinase I-like enzyme. Oncogene 1992; 7: 1361–1369.

    Google Scholar 

  25. Herrmann CP, Kraiss S, Montenarh M. Association of casein kinase II with immunopurified p53. Oncogene 1991; 6: 877– 884.

    Google Scholar 

  26. Meek DW, Simon S, Kikkawa U, Eckhart W. The p53 tumour suppressor protein is phosphorylated at serine 389 by casein kinase II. EMBO J 1990; 9: 3253–3260.

    Google Scholar 

  27. Addison C, Jenkins JR, Sturzbecher HW. The p53 nuclear localisation signal is structurally linked to a p34cdc2 kinase motif. Oncogene 1990; 5: 423–426.

    Google Scholar 

  28. Bischoff JR, Friedman PN, Marshak DR, Prives C, Beach D. Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2. Proc Natl Acad Sci USA 1990; 87: 4766–4770.

    Google Scholar 

  29. Milner J, Cook A, Mason J. p53 is associated with p34cdc2 in transformed cells. EMBO J 1990; 9: 2885–2889.

    Google Scholar 

  30. Price BD, Hughes-Davies L, Park SJ. Cdk2 kinase phosphorylates serine 315 of human p53 in vitro. Oncogene 1995; 11: 73–80.

    Google Scholar 

  31. Lees-Miller SP, Sakaguchi K, Ullrich SJ, Appella E, Anderson CW. Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of p53. Mol Cell Biol 1992; 12: 5041–5049.

    Google Scholar 

  32. Milne DM, Campbell DG, Caudwell FB, Meek DW. Phosphorylation of the tumor suppressor protein p53 by mitogenactivated protein kinases. J Biol Chem 1994; 269: 9253–9260.

    Google Scholar 

  33. Milne DM, Campbell LE, Campbell DG, Meek DW. p53 is phosphorylated in vitro and in vivo by an ultraviolet radiation-induced protein kinase characteristic of the c-Jun kinase, JNK1. J Biol Chem 1995; 270: 5511–5518.

    Google Scholar 

  34. Baudier J, Delphin C, Grunwald D, Khochbin S, Lawrence JJ. Characterization of the tumor suppressor protein p53 as a protein kinase C substrate and a S100b-binding protein. Proc Natl Acad Sci USA 1992; 89: 11627–11631.

    Google Scholar 

  35. Takenaka I, Morin F, Seizinger BR, Kley N. Regulation of the sequence-specific DNA binding function of p53 by protein kinase C and protein phosphatases. J Biol Chem 1995; 270: 5405–5411.

    Google Scholar 

  36. Jamal S, Ziff EB. Raf phosphorylates p53 in vitro and potentiates p53-dependent transcriptional transactivation in vivo. Oncogene 1995; 10: 2095–2101.

    Google Scholar 

  37. Mayr GA, Reed M, Wang P, Wang Y, Schweds JF, Tegtmeyer P. Serine phosphorylation in the NH2 terminus of p53 facilitates transactivation. Cancer Res 1995; 55: 2410–2417.

    Google Scholar 

  38. Hecker D, Page G, Lohrum M, Weiland S, Scheidtmann KH. Complex regulation of the DNA-binding activity of p53 by phosphorylation: differential effects of individual phosphorylation sites on the interaction with different binding motifs. Oncogene 1996; 12: 953–961.

    Google Scholar 

  39. Hupp TR, Meek DW, Midgley CA, Lane DP. Regulation of the specific DNA binding function of p53. Cell 1992; 71: 875– 886.

    Google Scholar 

  40. Hao M, Lowy AM, Kapoor M, Deffie A, Liu G, Lozano G. Mutation of phosphoserine 389 affects p53 function in vivo. J Biol Chem 1996; 271: 29380–29385.

    Google Scholar 

  41. Lohrum M, Scheidtmann KH. Differential effects of phosphorylation of rat p53 on transactivation of promoters derived from different p53 responsive genes. Oncogene 1996; 13: 2527– 2539.

    Google Scholar 

  42. Hall SR, Campbell LE, Meek DW. Phosphorylation of p53 at the casein kinase II site selectively regulates p53-dependent transcriptional repression but not transactivation. Nucleic Acids Res 1996; 24: 1119–1126.

    Google Scholar 

  43. Yan Y, Shay JW, Wright WE, Mumby MC. Inhibition of protein phosphatase activity induces p53-dependent apoptosis in the absence of p53 transactivation. J Biol Chem 1997; 272: 15220–15226.

    Google Scholar 

  44. Mukhopadhyay T, Roth JA. Induction of apoptosis in human lung cancer cells after wild-type p53 activation by methoxyestradiol. Oncogene 1997; 14: 379–384.

    Google Scholar 

  45. Maxwell SA, Roth JA, Mukhopadhyay T. Analysis of phosphorylated isoforms of the p53 tumor suppressor protein in human lung carcinoma cells undergoing apoptosis. Electrophoresis 1996; 17: 1772–1775.

    Google Scholar 

  46. Takahashi T, Nau MM, Chiba I, et al. p53: a frequent target for genetic abnormalities in lung cancer. Science 1989; 246: 491–494.

    Google Scholar 

  47. Maxwell SA, Mukhopadhyay T. Transient stabilization of p53 in non-small cell lung carcinoma cultures arrested for growth by retinoic acid. Exp Cell Res 1994; 214: 67–74.

    Google Scholar 

  48. Zhang WW, Fang X, Branch CD, Mazur W, French BA, Roth JA. Generation and indentification of recombinant adenovirus by liposome-mediated transfection and PCR analysis. Biotechniques 1993; 15: 868–872.

    Google Scholar 

  49. Maxwell SA, Zhang W-W. Cell type-specific regulation of p53 expression in non-small cell lung carcinoma cells. Oncol Repts 1995; 2: 81–87.

    Google Scholar 

  50. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB, Roth JA. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 1994; 54: 2287–2291.

    Google Scholar 

  51. Patterson RM, He C, Selkirk JK, Merrick BA. Human p53 expressed in baculovirus-infected Sf9 cells displays a two-dimensional isoform pattern identical to wild-type p53 from human cells. Arch Biochem Biophys 1996; 330: 71–79.

    Google Scholar 

  52. Selkirk JK, He C, Patterson RM, Merrick BA. Tumor suppressor p53 gene forms multiple isoforms: evidence for single locus origin and cytoplasmic complex formation with heat shock proteins. Electrophoresis 1996; 17: 1764–1771.

    Google Scholar 

  53. Price BC, Youmell MB. The phosphatidylinositol 3-kinase inhibitor wortmannin sensitizes murine fibroblasts and human tumor cels to radiattion and blocks induction of p53 following DNA damage. Cancer Res 1996; 56: 246–250.

    Google Scholar 

  54. Gabai VL, Zamulaeva IV, Mosin AF, et al. Resistance of Ehrlich tumor cells to apoptosis can be due to accumulation of heat shock proteins. FEBS Letts 1995; 375: 21–26.

    Google Scholar 

  55. Tishler RB, Lamppu DM, Park S, Price BD. Microtubule-active drugs taxol, vinblastine, and nocodazole increase the levels of transcriptionally active p53. Cancer Res 1995; 55: 6021–6025.

    Google Scholar 

  56. Tishler RB, Calderwood SK, Coleman CN, Price BD. Increases in sequence-specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents. Cancer Res 1993; 53: 2212–2216.

    Google Scholar 

  57. Tsukidate K, Yamamoto K, Snyder JW, Farber JL. Microtubule antagonists activate programmed cell death (apoptosis) in cultured rat hepatocytes. Am J Path 1993; 143: 918–925.

    Google Scholar 

  58. Kessis TD, Slebos RJ, Nelson WG, et al. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc Natl Acad Sci USA 1993; 90: 3988–3992.

    Google Scholar 

  59. Tsuji K, Ogawa K. Recovery from ultraviolet-induced growth arrest of primary rat hepatocytes by p53 antisense oligonucleotide treatment. Mol Carcinogen 1994; 9: 167–174.

    Google Scholar 

  60. Maxwell SA. Two-dimensional gel analysis of p53-mediated changes in protein expression. Anticancer Res 1994; 14: 2549– 2556.

    Google Scholar 

  61. Knippschild U, Milne D, Campbell L, Meek D. p53 Nterminus-targeted protein kinase activity is stimulated in response to wild-type p53 and DNA damage. Oncogene 1996; 13: 1387–1393.

    Google Scholar 

  62. Scheidtmann KH, Landsberg G. UV irradiation leads to transient changes in phosphorylation and stability of tumor suppressor protein p53. Int J Oncol 1996; 9: 1277–1285.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Thoracic Molecular Oncology, Department of Thoracic and Cardiovascular Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, 77030, USA

    T. Mukhopadhyay & J. A. Roth

  2. Department of Pathology and Laboratory Medicine, Texas A&M University, College of Medicine, College Station, Texas, 77843-1114, USA

    S. A. Acosta & S. A. Maxwell

Authors
  1. T. Mukhopadhyay
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. A. Roth
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. A. Acosta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. A. Maxwell
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mukhopadhyay, T., Roth, J.A., Acosta, S.A. et al. Two-dimensional gel analysis of apoptosis-specific p53 isoforms induced by 2-methoxyestradiol in human lung cancer cells. Apoptosis 3, 421–430 (1998). https://doi.org/10.1023/A:1009610603068

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1009610603068

Search

Navigation